Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07444632 · ClinicalTrials.gov registry record · Phase 1
Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid Malignancies
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT07444632: Recruiting Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT07444632 is a Phase 1 study that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 60 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07444632, a Phase 1 study, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
This is a phase 1 basket trial of TGFBR2 KO CAR27/IL-15 NK cells after lymphodepleting chemotherapy for patients with R/R B-NHL, HL, T-NHL or B-ALL.
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG TGFBR2 KO CAR27/IL-15 NK cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2026-05-28 |
| Est. Completion | 2032-09-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07444632
The ClinicalTrials.gov registry entry for NCT07444632 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT07444632 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07444632 about?
NCT07444632 is a clinical study titled "Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid Malignancies". This is a phase 1 basket trial of TGFBR2 KO CAR27/IL-15 NK cells after lymphodepleting chemotherapy for patients with R/R B-NHL, HL, T-NHL or B-ALL.
What is the current status of trial NCT07444632?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2026-05-28. Estimated completion is 2032-09-30.
What interventions are being tested in trial NCT07444632?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), TGFBR2 KO CAR27/IL-15 NK cells (DRUG).
Who is sponsoring clinical trial NCT07444632?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.